Stockscreener 앱 받기
1.80
3.74%
-0.07
시간 외 거래:
1.80
Aprea Therapeutics Inc 주식(APRE)의 최신 뉴스
Biotech Alert: Searches spiking for these stocks today - TipRanks
Aprea Therapeutics Advances ACESOT-1051 Clinical Trial with Key Patient Dosing - MSN
Aprea doses HPV+ HNSCC subject in cohort 5 of APR-1051 trial - Yahoo
Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Up 28.0% in March - Defense World
Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial - TradingView
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Brokers Issue Forecasts for APRE FY2025 Earnings - Defense World
Aprea Therapeutics Reports 2024 Financial Results and Updates on Clinical Innovations - MSN
What is Wedbush’s Estimate for APRE FY2029 Earnings? - Defense World
APRE stock touches 52-week low at $2.15 amid market challenges By Investing.com - Investing.com South Africa
APRE stock touches 52-week low at $2.15 amid market challenges - Investing.com India
Aprea Therapeutics (NASDAQ:APRE) Given “Outperform” Rating at Wedbush - Defense World
Aprea Therapeutics Advances Cancer Trials Amid Financial Progress - TipRanks
Aprea Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
APREA THERAPEUTICS Earnings Results: $APRE Reports Quarterly Earnings - Nasdaq
Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update - The Manila Times
Windtree Therapeutics and Evofem Announce Agreement to Lower Manufacturing Costs for PHEXXI - MyChesCo
Aprea Therapeutics (APRE) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Aprea Therapeutics Teams Up with MD Anderson for Preclinical HNSCC Research - MyChesCo
MD Anderson to explore Aprea’s WEE1 kinase inhibitor for HNSCC - BioWorld Online
Aprea Therapeutics partners with MD Anderson for cancer study - Investing.com India
Aprea Therapeutics Announces Agreement With MD Anderson Cancer Center To Explore Apr-1051 As A Potential Treatment For Head And Neck Squamous Cell Carcinoma (Hnscc) - Marketscreener.com
Aprea Therapeutics partners with MD Anderson for cancer study By Investing.com - Investing.com South Africa
Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC) - The Manila Times
Aprea Therapeutics to Showcase Expertise at Maxim Healthcare Virtual Summit - MSN
Aprea Therapeutics to Showcase Oncology Advances at Barcelona Symposium - MSN
Head-To-Head Comparison: Apellis Pharmaceuticals (NASDAQ:APLS) versus Aprea Therapeutics (NASDAQ:APRE) - Defense World
Insider Buyers Lose US$92k As Aprea Therapeutics Sheds US$3.2m - Simply Wall St
Aprea Therapeutics Strengthens Patent Portfolio to Advance Oncology Innovation - MSN
Aprea Therapeutics expands cancer drug patent portfolio - MSN
Ault Global (NYSEAMERICAN:DPW) Enters into Exchange Agreement with Orchid Finance LLC – Converts Outstanding Term Note for Convertible Promissory NoteThe financial landscape of Ault Global, trading under the ticker symbol DPW on the NYSE Amer - Defense World
Aprea Therapeutics Announces Update to Patent Portfolio in DNA Damage Response Cancer TherapeuticsDOYLESTOWN, PA, February 5, 2025 (GLOBE NEWSWIRE) – Aprea Therapeutics, Inc. (Nasdaq: APRE) provided an update on its existing patent portf - Defense World
FDA Greenlights Aprea Therapeutics' Investigational New Drug Application for Novel Cancer Treatment - MSN
Aprea Therapeutics provides update on existing patent portfolio - Yahoo Finance
Aprea Therapeutics expands cancer drug patent portfolio By Investing.com - Investing.com South Africa
Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care - The Manila Times
Myelodysplastic Syndrome Therapeutics Market Size in the 7MM was ~USD 2,800 Million in 2023, is expected to grow by 2034 | DelveInsight - The Globe and Mail
APRE News Today | Why did Aprea Therapeutics stock go up today? - MarketBeat
Aprea Therapeutics Discloses Unaudited Financials and Updates Corporate PresentationAprea Therapeutics, Inc. recently released an updated corporate presentation, alongside disclosing financial information as of December 31, 2024. The company shared - Defense World
StockNews.com Begins Coverage on SenesTech (NASDAQ:SNES) - Defense World
H.C. Wainwright sets target on Aprea stock, Buy rating on clinical update - MSN
HC Wainwright Reiterates Buy Rating for Aprea Therapeutics (NASDAQ:APRE) - Defense World
Kazia Therapeutics to sell 1.33M ADS at $1.50 in registered direct offering - Yahoo Finance
Aprea Therapeutics Updates ABOYA-119 Trial with Twice Daily Dosing - MSN
Chronic Lymphocytic Leukemia Therapeutics Market Size in the 7MM is projected to grow during the forecast period 2024-2034 and estimated DelveInsight - The Globe and Mail
1.23%
1.63%
자본화:
|
볼륨(24시간):